ESLA - NASDAQ

Estrella Immunopharma, Inc.

ESLA·NASDAQ

$1.17

+0.41%

HealthcareBiotechnology

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.34M

EPS-0.3500

P/E Ratio-3.34

Earnings Date06/03/2026

esla

Other Non-Cash Items

Last Annual Value

657.16K

3-Year CAGR

44%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Estrella Immunopharma, Inc. Competitors Analysis of Other Non-Cash Items

ESLA · NASDAQ

Company	Other Non-Cash Items	CAGR 3Y	CAGR 5Y	CAGR 10Y
Estrella Immunopharma, Inc. NASDAQ:ESLA	657.16K	N/A	N/A	N/A
Instil Bio, Inc. NASDAQ:TIL	26.09M	-24.3%	110.2%	N/A
Tevogen Bio Holdings Inc. NASDAQ:TVGN	-39.43M	N/A	N/A	N/A
Greenwich LifeSciences, Inc. NASDAQ:GLSI	0.00	N/A	N/A	N/A
BeyondSpring Inc. NASDAQ:BYSI	-6.24M	N/A	N/A	N/A
Cue Biopharma, Inc. NASDAQ:CUE	2.51M	203.2%	N/A	43.9%
MiNK Therapeutics, Inc. NASDAQ:INKT	3.71B	N/A	215.7%	N/A
MediciNova, Inc. NASDAQ:MNOV	878.83K	43.5%	32.3%	39.2%
OS Therapies Incorporated NYSE:OSTX	1.46M	-19.2%	-9.8%	N/A
Outlook Therapeutics, Inc. NASDAQ:OTLK	1580.49B	6434.3%	2053.1%	541.1%
Relmada Therapeutics, Inc. NASDAQ:RLMD	-41.84M	N/A	N/A	N/A

Estrella Immunopharma, Inc. Fair Value Envelope

ESLA · NASDAQ

Our analysis suggests that ESLA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.1698, this represents a potential HIDDEN relative to our calculated worth for Estrella Immunopharma, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.1698

Related Guides

Blog Categories

Continue your ESLA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.